Alterity Therapeutics Limited (ATHE)
Stock Price:
$1.41 USD
-0.05 (-3.10%)
Updated Oct 29, 2020 11:48 AM EDT - Market open
Key Info
| Market Cap |
31.76M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-13.46M |
| Shares Out |
22.60M |
| EPS (ttm) |
-0.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$1.41 |
| Previous Close |
$1.45 |
| Change ($) |
-0.05 |
| Change (%) |
-3.10% |
| Day's Open |
1.42 |
| Day's Range |
1.34 - 1.44 |
| Day's Volume |
47,842 |
| 52-Week Range |
0.28 - 5.15 |
More Stats
| Market Cap |
31.76M |
| Enterprise Value |
22.60M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.60M |
| Float |
n/a |
| EPS (basic) |
-0.90 |
| EPS (diluted) |
-0.90 |
| FCF / Share |
-0.63 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5,150 |
| Short Ratio |
0.04 |
| Short % of Float |
n/a |
| Beta |
0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.66 |
| Revenue |
n/a |
| Operating Income |
-13.94M |
| Net Income |
-13.46M |
| Free Cash Flow |
-9.45M |
| Net Cash |
9.16M |
| Net Cash / Share |
0.41 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-58.40% |
| ROE |
-113.53% |
| ROIC |
-12,239.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $1.41
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | 0.14 | 0.18 | 0.36 | 0.15 | 0.19 | 0.16 |
| Revenue Growth | - | - | - | - | -19.33% | -51.39% | 141.12% | -19.18% | 19.55% | - |
| Gross Profit | - | - | - | - | 0.14 | 0.18 | 0.36 | 0.15 | 0.19 | 0.16 |
| Operating Income | -13.94 | -17.75 | -11.32 | -10.04 | -13.34 | -16.92 | -20.40 | -11.10 | -6.55 | -5.43 |
| Net Income | -13.46 | -12.34 | -8.27 | -7.54 | -7.73 | -5.89 | -13.33 | -7.79 | -5.24 | -6.43 |
| Shares Outstanding | 895 | 616 | 534 | 534 | 534 | 503 | 428 | 339 | 288 | 248 |
| Earnings Per Share | -0.90 | -1.20 | -0.93 | -0.85 | -0.87 | -0.70 | -1.87 | -1.38 | -1.09 | -1.56 |
| Operating Cash Flow | -9.43 | -13.95 | -6.25 | -5.87 | -7.42 | -10.87 | -13.54 | -7.95 | -6.85 | -4.56 |
| Capital Expenditures | -0.02 | -0.01 | -0.06 | -0.03 | - | -0.03 | -0.02 | -0.02 | -0.03 | -0.01 |
| Free Cash Flow | -9.45 | -13.96 | -6.31 | -5.89 | -7.42 | -10.90 | -13.56 | -7.97 | -6.87 | -4.57 |
| Cash & Equivalents | 9.20 | 14.40 | 15.24 | 21.88 | 28.59 | 34.91 | 34.17 | 13.35 | 5.64 | 8.84 |
| Total Debt | 0.03 | - | - | - | - | 0.01 | 0.10 | 0.87 | 0.34 | 0.36 |
| Net Cash / Debt | 9.16 | 14.40 | 15.24 | 21.88 | 28.59 | 34.90 | 34.07 | 12.48 | 5.30 | 8.48 |
| Assets | 9.91 | 19.91 | 18.73 | 25.28 | 33.73 | 41.83 | 41.64 | 17.07 | 7.34 | 9.01 |
| Liabilities | 2.76 | 3.36 | 2.64 | 1.59 | 2.36 | 2.72 | 3.95 | 3.10 | 1.72 | 2.08 |
| Book Value | 7.15 | 16.55 | 16.08 | 23.69 | 31.37 | 39.11 | 37.69 | 13.97 | 5.62 | 6.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Alterity Therapeutics Limited |
| Employees |
12 |
| CEO |
Geoffrey Paul Kempler |
Stock Information
| Ticker Symbol |
ATHE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ATHE |
Description
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.